Want to see SE:BIOEX full AI Analyst Report?
Top Page
Bioextrax AB
(BIOEX)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr2.50
▼(-21.63% Downside)
Action:Reiterated
Date:07/02/26
The score is primarily held down by weak financial performance—persistent losses, mostly negative gross profit, declining recent revenue, and ongoing negative operating/free cash flow with higher cash burn in 2025—despite the benefit of having no reported debt. Technicals are mixed/neutral and do not offset the fundamental risks, while valuation is also pressured by negative earnings (negative P/E) and no indicated dividend yield.
Positive Factors
Conservative balance sheet (no reported debt)
Zero reported debt materially reduces refinancing and interest-rate risk for a small biotech. This structural conservatism preserves optionality for R&D and commercialization timelines, lowering the probability that operating shortfalls immediately force distress financing or hurried asset sales.
Negative Factors
Structural unprofitability
Persistently negative gross margins and deep operating losses signal the company's cost base exceeds current revenue capability. This is a structural barrier to sustainable earnings: without consistent margin improvement or materially higher revenue, profitability remains unlikely and constrains reinvestment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet (no reported debt)
Zero reported debt materially reduces refinancing and interest-rate risk for a small biotech. This structural conservatism preserves optionality for R&D and commercialization timelines, lowering the probability that operating shortfalls immediately force distress financing or hurried asset sales.
Read all positive factors
Bioextrax AB (BIOEX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr126.14M
Dividend YieldN/A
Average Volume (3M)82.14K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth45.29%
EPS Growth7.02%
CountrySE
Employees14
SectorIndustrials
Sector Strength72
IndustryWaste Management
Share Statistics
EPS (TTM)-0.35
Shares Outstanding47,601,730
10 Day Avg. Volume104,394
30 Day Avg. Volume82,137
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)5.23
Price to Sales (P/S)146.53
P/FCF Ratio-4.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.37
Revenue Forecast (FY)kr2.34M
Bioextrax AB Business Overview & Revenue Model
Company Description
Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granu...
How the Company Makes Money
Bioextrax makes money primarily by commercializing its industrial biotechnology capabilities and resulting products and/or process technologies. Key revenue streams can include (i) sales of bio-based products or ingredients produced using its proc...
Bioextrax AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 757.00K | 515.00K | 2.06M | 395.00K | 275.76K |
| Gross Profit | -16.43M | -915.00K | 718.00K | -18.64M | -11.29M |
| EBITDA | -17.24M | -16.18M | -20.65M | -18.19M | -10.18M |
| Net Income | -17.70M | -17.34M | -21.51M | -18.67M | -10.53M |
Balance Sheet | |||||
| Total Assets | 24.73M | 29.00M | 22.52M | 37.92M | 12.64M |
| Cash, Cash Equivalents and Short-Term Investments | 3.93M | 17.27M | 13.40M | 27.53M | 8.98M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.51M | 2.94M | 1.98M | 6.15M | 5.14M |
| Stockholders Equity | 21.21M | 26.06M | 20.54M | 31.77M | 7.50M |
Cash Flow | |||||
| Free Cash Flow | -26.20M | -18.99M | -24.41M | -24.38M | -9.45M |
| Operating Cash Flow | -26.05M | -18.78M | -23.31M | -17.60M | -8.48M |
| Investing Cash Flow | -152.00K | -215.00K | -1.10M | -6.78M | -975.13K |
| Financing Cash Flow | 12.86M | 22.86M | 10.28M | 42.94M | 16.38M |
Bioextrax AB Technical Analysis
Positive
3.19
Price Trends
2.56
Positive
2.68
Negative
2.54
Positive
Market Momentum
0.02
Negative
55.28
Neutral
50.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOEX, the sentiment is Positive. The current price of 3.19 is above the 20-day moving average (MA) of 2.53, above the 50-day MA of 2.56, and above the 200-day MA of 2.54, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 55.28 is Neutral, neither overbought nor oversold. The STOCH value of 50.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOEX.
Bioextrax AB Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
51 Neutral | kr97.20M | 29.33 | 5.40% | ― | 9.35% | -59.04% | |
48 Neutral | kr115.60M | -5.29 | -1.58% | ― | -8.81% | 33.71% | |
47 Neutral | kr254.90M | -0.59 | -20.69% | ― | -73.84% | -55942.86% | |
47 Neutral | kr87.87M | -12.11 | -17.60% | ― | 65.80% | 73.02% | |
46 Neutral | kr126.14M | -6.08 | -94.54% | ― | 45.29% | 7.02% | |
43 Neutral | kr50.57M | -1.72 | -25.32% | ― | -66.96% | -1530.40% |
* Industrials Sector Average
SE:BIOEX
Bioextrax AB
2.65
-0.23
-8.15%
SE:SES
Scandinavian Enviro Systems AB
0.23
-0.57
-71.36%
SE:AXOLOT
Axolot Solutions Holding AB
0.28
-0.21
-43.35%
SE:LEVEL
Nordic LEVEL Group AB Class B
0.33
-0.31
-48.28%
SE:CIRCHE
CirChem AB
0.69
-1.35
-66.24%
SE:CLEM
Clemondo Group AB
7.02
-2.23
-24.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.